{
    "title": "Sarepta slumps as muscle disorder trial data signals 'uphill battle'",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12693549/Sarepta-slumps-muscle-disorder-trial-data-signals-uphill-battle.html",
    "date": "2023-10-31",
    "keywords": [
        "approval",
        "therapy",
        "gene",
        "disorder",
        "trial",
        "latestage",
        "treatment",
        "health",
        "analyst",
        "market",
        "study",
        "tuesday",
        "musclewasting",
        "goal",
        "stock",
        "price",
        "uncertainty",
        "growth",
        "sarepta",
        "battle",
        "label",
        "gil",
        "blum",
        "elevidys",
        "june",
        "regulator",
        "duchenne",
        "dystrophy",
        "dmd",
        "midstage",
        "version",
        "dystrophin",
        "protein",
        "patient",
        "ability",
        "therapys",
        "effectiveness",
        "motor",
        "function",
        "safety",
        "evidence",
        "capture",
        "baird",
        "equity",
        "research",
        "skorney",
        "company",
        "age",
        "ratio",
        "benchmark",
        "peer",
        "biomarin",
        "bleeding",
        "year",
        "reporting",
        "mariam",
        "sunny",
        "bengaluru",
        "editing",
        "syamnath"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}